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ABSTRACT
Objectives There is a need in clinical genomics for
systems that assist in clinical diagnosis, analysis of
genomic information and periodic reanalysis of results,
and can use information from the electronic health record
to do so. Such systems should be built using the concepts
of human-centred design, fit within clinical workflows and
provide solutions to priority problems.
Methods We adapted a commercially available diagnostic
decision support system (DDSS) to use extracted
findings from a patient record and combine them with
genomic variant information in the DDSS interface. Three
representative patient cases were created in a simulated
clinical environment for user testing. A semistructured
interview guide was created to illuminate factors relevant
to human factors in CDS design and organisational
implementation.
Results Six individuals completed the user testing
process. Tester responses were positive and noted good fit
with real-world clinical genetics workflow. Technical issues
related to interface, interaction and design were minor
and fixable. Testers suggested solving issues related to
terminology and usability through training and infobuttons.
Time savings was estimated at 30%–50% and additional
uses such as in-house clinical variant analysis were
suggested for increase fit with workflow and to further
address priority problems.
Conclusion This study provides preliminary evidence for
usability, workflow fit, acceptability and implementation
potential of a modified DDSS that includes machine-
assisted chart review. Continued development and
testing using principles from human-centred design
and implementation science are necessary to improve
technical functionality and acceptability for multiple
stakeholders and organisational implementation potential
to improve the genomic diagnosis process.

INTRODUCTION
Clinical decision support (CDS) integrated
into electronic health records (EHRs) has
long been considered a promising way to
improve patient outcomes and decrease inefficiencies.1–4 It is also recognised that CDS

Summary
What is already known?
►► There is a need in clinical genomics for tools that

assist in analysis of genomic information and can
do so using information from the electronic health
record.
►► Such tools should be easy to use, fit within clinical
workflows, and provide solutions to priority problems as defined by clinician end-users.
►► Natural language processing (NLP) is a useful tool to
read patient records and extract findings.

What does this paper add?
►► We demonstrated the use of Human-centred design

and implementation science principles in a simulated environment for assessment of a new version of a decision support tool prior to large-scale
implementation.
►► This study provides preliminary evidence that a
clinical decision support tool with machine-assisted
chart review is acceptable to clinical end-users, fits
within the clinical workflow, and addresses perceived needs within the differential diagnosis process across all Mendelian genetic disorders.
►► Terminology codes for diagnostic decision support
systems should have levels of granularity tuned
to the sensitivity and specificity appropriate to its
various functions, for example, NLP versus chart
documentation.

must be designed with the user in mind,
fitting the concepts of human-centred design
with computer interfaces at the individual
clinician level.1 5 Design alone, however, is
insufficient to facilitate implementation. For
CDS to impact care and patient outcomes, it
must fit within clinician workflow and provide
a solution to a priority problem for the clinician and the healthcare system.4 6–8
Diagnostic decision support systems
(DDSSs) are a key type of CDS needed in
genomics to supplement a shortage of
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trained clinicians and address the inherent complexity
of genomic diagnosis.9 10 This complexity arises from
the heterogeneous nature of genetic diseases, the variable expression in patients and the degree of overlap
in findings (ie, signs, symptoms and test results) among
genetic conditions, sometimes differentiated only by
onset age of individual findings.11 Position statements
and a systematic review note two new functions needed
for DDSSs in genomics: (1) a cost-
effective, regular
approach to re-evaluation of patient cases in light of
new findings or genetic knowledge, when testing does
not immediately yield a diagnosis; and (2) developing
machine-assisted chart review.12 13 Most genomic patient
records are extensive with input from by multiple clinicians, such that manual review is prohibitively time-
consuming; resulting in added costs from repeated or
unnecessary tests and increased risk of missed information that could have facilitated timely diagnosis. Because
most of the relevant information is in unstructured
clinical notes, approaches such as natural language
processing (NLP) are needed to automate and assist
this manual process.
To address both re-
evaluation and automation, we
adapted a commercially available DDSS already capable
of incorporating genomic sequencing data to perform
automated chart review and present the information
to a clinician in the form of findings obtained through
structured data mining and NLP of an EHR. We then
created clinical case vignettes to simulate the real-
world clinical diagnostic workflow for user testing. The
goal was to provide preliminary evidence of usability,
perceived fit with clinical need and workflow, and
potential for implementation into the real-world clinical environment.

METHODS
Setting
Development of the clinical case vignettes, simulated
EHR environment, and user testing were conducted at
Geisinger, a healthcare system in rural Pennsylvania.
Adapting a DDSS for machine-assisted chart review of clinical
findings
We adapted SimulConsult’s Genome-Phenome Analyzer,
as it is the one DDSS that allows for detailed analysis of
clinical information, including pertinent negatives, findings onset information and frequency and treatability of
diseases. It has also been shown to be accurate and helpful
in clinical diagnosis, including interpreting genomic
results.14–16 Described in detail elsewhere,11 14 15 SimulConsult correlates annotated variant call files (VCFs) with
patient-specific clinical and family history information;
dependent
and the underlying algorithms include age-
Bayesian pattern-
matching and computational metrics
of usefulness and pertinence. SimulConsult also generates a Patient Summary for saving interim patient findings and a customisable genomic return of results (RoR)
report shown in previous research to be effective for
facilitating standardised communication for patients and
referring clinicians.17–20 When clinicians enter findings,
the DDSS returns a ranked list of candidate diseases and
suggestions of other findings to check, ranked by usefulness in narrowing the differential diagnosis in a way that
accounts for cost and treatability; thus facilitating the iterative approach of information gathering in diagnosis.21 22
For each finding, th presence (with onset age) or absence
can be specified (figure 1).
We used the Logica platform to create a simulated EHR
and the cTAKES tool with the Unified Medical Language

Figure 1 SimulConsult main interface showing ranked list of candidate diseases and guidance for entering finding presence
(or absence) with onset age.
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Table 1 Adaptations made to existing DDSS to create GPACSS
Adaptation

Component

Approach

Overall design

SMART-on-FHIR enabled
EHR

►► Logica platform (https://www.logicahalth.org/; formerly Health Services

Archive

►► Custom archive stores key files
►► RESTful interface.

User interface

►► SMART-on-FHIR application (GPACSS FHIR app client, figure 2).
►► Interface allows user access to DDSS directly from patient record.
►► Choice to launch with no findings or with findings previously saved.

Coordination

►► GPACSS ‘Coordinator’ application programming interface (API) saves the NLP

Coordination and
communication

Platform Consortium)

output

►► Matching of UMLS codes in NLP output to DDSS findings
►► Send the matched flagged findings to the DDSS at launch (figure 2)

Natural language
processing

Extraction of findings

►► NLP: open source Apache cTAKES V.4.0.23
►► cTAKES default modules to handle sentence boundary detection, tokenisation,

normalisation, tagging parts of speech, recognising named entities and
negation.
►► cTAKES pretrained module to recognise UMLS concepts in text.
Mapping in DDSS

►► DDSS findings mapped within the DDSS to one or more UMLS and Human

Phenotype Ontology codes.

►► Mapping strategy minimises false negatives in term capture while tolerating

false positives (identifying information unrelated or irrelevant to the diagnostic
process).

Display in DDSS

►► Findings identified by NLP display a flag icon.
►► Clicking the flag enables viewing of metadata.

DDSS, diagnostic decision support system; EHR, electronic health record; GPACSS, Genotype-Phenotype Archiving and
Communication System with SimulConsult; UMLS, Unified Medical Language System.

System (UMLS) module23 for NLP of patient notes.
Steps in adaption included (1) mapping DDSS findings to Human Phenotype Ontology (HPO) and UMLS
codes, including creation of hundreds of new HPO terms
resulting in creation of new UMLS concepts, (2) using
results from NLP analysis of EHR notes to flag ‘Mentions’
of the findings used by the DDSS and (3) augmenting
the DDSS’s interface to present the flagged findings with
contextual information needed to clinically assess the
information (table 1).

The architecture of the resulting prototype, called the
Genotype-
Phenotype Archiving and Communication
System with SimulConsult (GPACSS), is shown in figure 2.
Clinician review of the flagged findings created from
the automated findings search using NLP is facilitated
through flag icons (figure 3). Through this ‘machine-
assisted’ chart review, the clinician reviews flagged findings and decides whether and how to specify presence
(with a particular onset) or absence (or omit) as shown
in figure 1. The mapping of DDSS findings to multiple

Figure 2 Architecture of the Genotype-Phenotype Archiving and Communication System with SimulConsult (GPACSS). The
key components are the coordination/archiving system, the DDSS and the NLP. DDSS, diagnostic decision support system;
EHR, electronic health record; NLP, natural language processing.
Kulchak Rahm A, et al. BMJ Health Care Inform 2021;28:e100331. doi:10.1136/bmjhci-2021-100331
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Figure 3 Flagged findings with EHR text display for DDSS. A finding having a flag icon indicates that information was found in
the EHR. Clicking the flag shows the various mentions of the flagged finding. DDSS, diagnostic decision support system; EHR,
electronic health record.

UMLS concepts was chosen to minimise false negatives
in concept identification; relying on the user decisions
about findings and the limited set of UMLS concepts to
minimise false positives (table 2).
Creating simulated cases
Three cases of increasing complexity were created using
real but deidentified clinical phenotypic and time course
data from medical notes of Geisinger patients with known
genetic diagnoses (online supplemental table 1). Cases
were selected for conditions of varying complexity yet
relatively common in the context of rare disease and

where diagnosis might be difficult using phenotype
alone. Simulated cases were created by research assistants trained in capturing information from the EHR,
supervised by a practicing Geisinger clinician certified
in genetics and informatics. The three final cases were
reviewed by a second Geisinger physician certified in
genetics and informatics prior to user testing.
Case vignettes for the test scenarios assumed that some
patient characterisation was previously noted by the clinician and genomic results were now available and could
be interpreted with clinical information available in the

Table 2 Solutions for mnimising false positives and negatives identified through NLP and DDSS by clinician review
False negative/positive problem

Solution included in GPACSS

Minimising false negatives on NLP flagging of
findings

►► Include parent and child codes (eg, finding of intellectual disability in DDSS

Minimising false positives through the DDSS
Usefulness metric
Minimising false positives through clinician
verification

includes codes for developmental delay and particular types of intellectual
disability).
30
►► Use DDSS usefulness algorithm to display flagged findings; thus
prioritising data of greater relevance and de-prioritising data of low
relevance for clinician review.
►► Use flag icon to indicate findings identified through NLP (figure 3).
►► Clinician clicks the flag icon to display information needed to assess
reliability, presence or absence, and onset.
►► Information displayed from the EHR includes date of chart note, observer
identity and three sentences of chart note (sentence with finding plus
preceding and subsequent sentence).

DDSS, diagnostic decision support system; EHR, electronic health record; GPACSS, Genotype-Phenotype Archiving and Communication
System with SimulConsult; NLP, natural language processing.
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EHR (online supplemental figure A). For the three cases,
a total of five findings were used as initial information
before the genomic results, with three (one per case)
being flagged findings identified through NLP. This
created a ‘near live’24 experience within the simulated
EHR for user testing while limiting the expense and time
of EHR integration during this preliminary phase.
User testing methods
Participants
GPACSS is both a DDSS and communication tool to facilitate utilisation of genomic and phenotypic information
available in the EHR by all clinicians to improve patient
care within a healthcare system. Therefore, we purposively selected primary testers from Geisinger staff representative of current end users of the genome-phenome
analyzer. Because a limited number of individuals at
Geisinger regularly engage in using genomic information
for differential diagnosis, we followed guidance recommending 3–5 evaluators for preliminary usability testing.25
A group of secondary testers (inclusive of a pilot tester)
with other roles in the genetic testing and interpretation
process were purposively selected for potential broader
utilisation in the healthcare system.
Testing sessions
At the beginning of each session, testers viewed a 4 min
training video (https://simulconsult.com/videogpacss)
beginning from saved patient findings, then importing a
VCF, and review of flagged findings to make a diagnosis
and create a customisable patient-friendly RoR report.
A semistructured interview guide (online supplemental
file 3) was created to elucidate factors relevant to human
factors in CDS design (information, interaction, interface)1 5 26 and organisational implementation (acceptability, perceived need, feasibility, workflow fit).27 We
used a think aloud24 approach where testers were asked
to verbalise thoughts while using the GPACSS prototype
with the interviewer asking questions as needed and at
key points in the testing to create a cognitive walkthrough
with heuristic evaluation.25 28 Testers were invited via
direct contact from study staff and provided a description
of the study. At the beginning of each session, study staff
reviewed a study information sheet and obtained verbal
consent to participate. Test sessions lasted 2 hours and
testers received a US$100 gift card.
An experienced interviewer (AKR) and observer (MAW)
from Geisinger worked with each tester to imagine using
GPACSS for each test scenario. The interview and process
were piloted with a cancer genetic counsellor reviewing
one test vignette. At the end of the session, testers were
asked a series of study-specific questions using a 0–10
rating scale (hard to easy) to rate the overall usefulness,
satisfaction, and navigation. Transcripts were created
from the audio portion of each session and the computer
screen was video recorded to capture tester movement
through GPACSS.

Analysis
Two Geisinger coders (MAW and JCR) viewed each user
test session recording, read transcripts and created a
codebook of themes identified across sessions. Transcripts were coded and the corresponding quotes were
organised into a matrix using the three categories of CDS
components (information, interface and interaction)
identified by Miller et al,1 and categories of acceptability,
perceived need, feasibility and workflow fit according
to Rogers’ Diffusion of Innovations in organisations
constructs.27 Coders analysed transcripts independently
and reviewed for agreement with discrepancies resolved
by the primary author.

RESULTS
Three clinicians currently using genomic information
to diagnose patients participated as primary testers: a
paediatric geneticist (orders exomes daily), internal
medicine physician (orders 4–5 exomes per month)
and a paediatric genetic counsellor. Three additional
clinicians participated as secondary testers; representing
broader usability within the healthcare system: the pilot
tester (cancer genetic counsellor), a laboratory director
(conducts variant interpretation) and a laboratory
genetic counsellor (conducts variant analysis).
GPACSS usability: human factors of CDS design
Overall impression of the prototype was positive. Testers
raised general issues relevant to human factors in CDS
design.1 5
Interface
Testers liked the flagged findings (figure 3), the contextual information for each mention in the EHR, and the
rank ordering of flagged findings by usefulness. The visualisation of the evolving differential diagnosis and the
automated RoR report for sharing with patients and referring clinicians, including the ability to save and access this
report from the EHR were also appreciated.
The interface was noted to be complex, but testers
stated this was expected due to the inherent complexity
of genetic diagnosis and that they anticipated a learning
curve to develop proficiency. Placement, positioning and
the multiple presentation layers (text and graphics in the
interface)1 were well liked. In particular, the ‘Assess diagnosis’ display was noted as valuable because it made transparent the logic used by the DDSS in comparing patient
findings to information about the disease. Of note, each
tester interpreted differently the meaning of the graphical bars and shading, however, this did not hinder their
ability to make the diagnosis, and the bar itself was appreciated as a design feature. To help with interpretation,
more labelling was suggested (table 3).
Interaction
Testers were thoughtful and purposeful using GPACSS.
Notably, in case 3 (the most complex case), one primary
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Table 3 GPACSS usability: human factors of CDS design and Organisational implementation factors through tester
Experiences*
Human factors of
CDS design

Interface

‘More training would be good… unless I was doing it all the time for all of my patients, every
step, I might not realise that some of the features are available…’(Tester 3)
‘These bars are different lengths, so I assume it’s having something to do with
frequencies… so I'm not sure why this part is purple…if there were something [on the
assess diagnosis tab] that said this is 100% over here and this is 0% over here, that would
kind of help, if I knew that that was the case… I'm not sure what these other colors are
referring to.’(Tester 5)

Interaction

‘To me, the green bar in it shows me they are confident that this genetic variant aligns with
the phenotypic markers that we have identified. I don't necessarily know how far the bars
will tell me they're confidence in pathogenic vs VUS.’(Tester 3)
‘It’s going to take a lot to learn. A lot of clicking back and forth and it’s not super intuitive
but I get it. So, the report gets generated and that becomes part of the record. I can see
how that can be helpful because it has now particular phenotypical diagnosis and even
genetic finding’(Tester 2)

Information

‘The term pertinent gene zygosity is not something I would normally make part of my
lexicon…I have a general sense of the term zygosity but I can't remember the last ten years
using that term in any of my discussions in clinical care or genetics in some of the cases I
found what’s their zygosity’ (Tester 2)
‘But the variant severity score doesn't mean anything to me personally. To me it’s easier
to know, if you verify know the true classification they are giving it… Pathogenic, likely
pathogenic VUS benign.’ (Tester 3)
‘I think this one is nice [the ‘Mention’ displayed in a flagged finding]. Whenever someone
says it had been noticed earlier by, it’s nice when someone is talking about their niece or
nephew, or like a proband cousin, they are saying they had myopia and I remember them
having glasses before they were 5 years old.’ (Tester 3)

Organisational
Implementation
Factors

Acceptability ‘I would use it most of the time. To me, this is the frontier of genomic medicine and I look at
my role as not only taking care of a patient but figuring out how we make genomics part of
everyday medical practice. The useful things in the chart, genetics people can now get to
right away’.(Tester 2)
‘…Typing them up, writing the summary [of all the patient findings in the chart]. If I could
see what’s been flagged in the chart, see what has not actively been flagged and decide do
I need to go back and look at it or not. It would save my time’ (Tester 3)
‘I think the interface is really good, in that you have that ability to explore those variants that
may or may not make it on the reports that we get now, so you can drill deeper if you want.
(Tester 5)
Perceived
Need

‘…The report is a great idea for highlighting why you think it’s [the care instructions]
important, [in] a standard format… The average primary care physician that gets the genetic
testing reports, says I don't know what this means at all. I think this [the Prognosis Table] is
a step towards making it more understandable.’ (Tester 2)
‘Everything’s there [in the chart] and the question is how easy is it to find. I'm sure if you're
a malpractice lawyer you get very good at pulling stuff out of these charts and asking why
didn't you see that. Yet I can't look at everything.’ (Tester 2)
‘This is stuff that you are doing anyway… you could make your note a lot shorter and just
refer to that document [the automated Summary] … I like the idea that you can explore.
Clinical genetics now is limited on time.’ (Tester 5)

Workflow Fit

‘It’s nice because it helps guide me… it’s very easier for me to realize that Prader–Willi is
associated with narcolepsy…’(Tester 3)
‘I think the nice part is I don't have to go searching myself to find all the signs and
symptoms associated with it and potentially miss something, that I may not know is a less
common finding or feature of the condition. That actually could be beneficial for a provider
or for us to give to the testing lab, to say these are all symptoms that we see, and then
analyzing the data’ (Tester 3)

*Comments from primary user-testers only (testers experienced with differential diagnosis of genetic conditions through sequencing): n=3;
paediatric genetic counsellor, paediatric geneticist, internist ordering 4–5 exomes in the past month.
CDS, clinical decision support; GPACSS, Genotype-Phenotype Archiving and Communication System with SimulConsult.
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tester did not immediately choose the top diagnosis
offered by GPACSS. Supported by the data displayed, the
tester indicated that to make a definitive diagnosis they
would next evaluate for the second-ranked disease—as
that condition had a test that was easy and accurate and
the condition was also more treatable—indicating utilisation of the DDSS as intended and consistent with clinical
diagnostic decision making.
Testers initially expressed concern around ‘too many
clicks’ and ‘click fatigue’ but noted as they progressed
through the cases that the clicking was unavoidable and
necessary. For example, they saw value in taking the time
to correctly specify onset information (which requires
clicking and cognitive load in the DDSS), as this is part of
the genetic diagnostic process. ‘Cognitive Load’ in DDSS
testing refers to additional thinking required to interact
with the tool, and the general recommendation is to
minimise this in CDS design.1 Testers who commented on
the cognitive load required to review flagged findings and
choose age of onset noted the cognitive load as similar to
completing this task without GPACSS.
Information
Testers appreciated resources such as the hover feature
that revealed synonyms to findings and requested even
more hovers and infobuttons. Confusion over some
terminology occurred, notably ‘zygosity’ and ‘severity
score,’ when reviewing the genomic variants; as only some
testers located the explanatory resource for these terms.
The fact that the EHR ‘Mentions’ displayed in flagged
findings were sometimes triggered by parent or by child
concepts was noticed by all testers, and some stated
the findings used in the DDSS were not as granular as
they were expecting. Regardless, testers recognised and
emphasised the importance of being able to review the
‘Mention’ information from the EHR and manually
adjust for any false positives and false negatives from the
NLP process.
GPACSS usability: organisational implementation factors
Acceptability
For the primary testers, satisfaction averaged 8.5 out of
10 (range 8–9.5) and navigation ease averaged 8 out of
10 (range 7.5–9). All three felt GPACSS would save time
throughout the clinical process, with one primary tester
estimating it at 30%–50%. Specific value in time saved was
noted for chart review by all testers.
Perceived need
The RoR report and detailed prognosis table20 generated
in each scenario was highly valued for being standardised
and for its ability to communicate complex genetic information to patients and other clinicians (table 3). The RoR
report was also noted as an improvement over current
laboratory reports; with one tester stating it was ‘where
the most utility would be’(Tester 4).
Testers exhibited learning and familiarity with
GPACSS as they progressed through the testing session;

appreciating the DDSS assistance as each vignette
increased in complexity; noting ‘It takes it [clinical diagnosis and diagnostic thinking] to a higher level’. [Tester
2]. Primary testers expressed readiness to adopt the
tool in clinical practice; and one (paediatric geneticist)
suggested GPACSS could also serve as a differential diagnosis training tool for medical students and residents in
their clinic.
Two secondary testers (lab director and variant analyst)
expressed enthusiasm that GPACSS could fill a need for
in-house sequencing laboratories because full EHR data
would be available during sequence interpretation. These
testers also hypothesised that the ability to periodically
re-
analyse an existing VCF in minutes using GPACSS
would improve the diagnosis rate over time.
Workflow fit
The three primary testers noted that the GPACSS process
as tested fit with their clinical workflow diagnosing
genetic conditions. As an added benefit, they described
how using GPACSS also helped them learn about diseases
and associated findings with which they were less familiar
(table 3).
The three secondary testers questioned GPACSS fit
with a clinical genetic testing workflow in which only a
report with variants labelled as to pathogenicity and association with a condition (implying a clinical diagnosis) is
received from an external lab. However, they did identify value and possible workflow fit for situations with
uncertainty as to the diagnosis after sequencing or where
flagged findings and the usefulness ranking would allow
clinicians to review the EHR with flagged findings in light
of the genomic information to make the diagnosis.

DISCUSSION
We provide preliminary evidence through user testing in
a simulated real-world clinical workflow that the combination of NLP with a CDS tool optimised to support the
clinical process of differential diagnosis may address the
needs of those involved in this complex task. Such assessment of fit is critical if CDS is to fulfil the promise of standardising and improving care.1 4 5 8
Technical issues related to the interface and interaction of CDS design were minor and fixable; as were issues
with design layout. Despite initial remarks on the number
of clicks and cognitive load, testers acknowledged these
as necessary to the genetic diagnosis process and no
different than without the DDSS. Other issues related
to terminology and usability could be solved and evaluated in future usability studies through a combination
of training, added infobuttons and experience using
GPACSS. Some of the technical gaps noted and additions requested by testers are addressed within GPACSS,
however, the 4 min training video was created to provide
enough instruction only to facilitate user testing. These
results, therefore, provide direction for training and
ongoing reference materials for future implementation.
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For CDS to be acceptable and implemented by clinicians and organisations, it must fit with the real-world
workflow and must present a solution to a perceived
need.5 27 All primary testers identified ways GPACSS
added such value and fit and noted ways GPACSS filled
multiple needs in their diagnostic workflow. Workflow
fit was highest among primary testers but opportunities
for workflow fit were described by all testers. GPACSS was
also noted as acceptable for implementation by all testers
regardless of individual issues identified and suggestions
for technical improvements.
LIMITATIONS
To facilitate user testing of GPACSS in the context of clinical workflow prior to full integration and implementation, simulations of the real-world were required. Because
this study used the Logica EHR simulation, benefits or
drawbacks of GPACSS in a production EHR could not
be directly observed. Also, full annotations for the causal
variants were not included in the variant table for the
simulated patients limiting full assessment of the value
of the DDSS in variant interpretation. This impacted the
understanding of the ‘severity score’ by all testers, as the
annotation information that would have been provided
for a real patient was not included for the simulated
cases. Finally, the generic cTAKES NLP using the UMLS
concepts found only 20 of the 30 (67%) pertinent positive concepts within the test cases that a paediatric neurologist (MMS) identified manually. This was sufficient for
GPACSS to generate the correct differential diagnosis for
user testing, as further enrichment of the generic NLP
to improve detection and avoid false positives was out of
scope for this preliminary user testing.29 Subsequent automated search for UMLS terms for flagging and addition
of a separate stage of text search enrichment for terms
missed by the NLP such as ‘tall’ improved NLP yield to 30
of 30 (100%).
This simulated EHR and user testing were a necessary
first step and provide data to guide implementation of
GPACSS. NLP improvements and additional beta testing
within an actual EHR, in real-world clinical workflows,
with real patient results and in real-world clinical workflows will be necessary to fully assess individual user-level
and organisational-level facilitators and barriers to use,
implementation and impact on clinical care. Such studies
are currently in progress.
CONCLUSIONS
This study provides preliminary evidence for the usability,
workflow fit, acceptability and implementation potential
of a DDSS that includes machine-assisted chart review.
Overall, responses suggest the GPACSS prototype is
usable based on technical CDS and human-
centred
design criteria, addresses perceived clinical need, and has
good fit within the real-world clinical workflow of genetic
testing and diagnosis. Further development is needed to
8

improve usability for multiple clinical stakeholders and
organisational implementation.
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Supplemental table 1
Supplemental Table 1. Creating and processing simulated patients* in GPACSS for user testing in
simulated real-time clinical workflow

Simulation aspect
Phenotype

Process used in simulation
All findings discussed in the original Geisinger EHR text were retained
but notes were manually rewritten by changing narrative to remove
identifying information and prevent re-identification, shifting dates
while maintaining chronological relationships, and shifting numeric
values while maintaining appropriate range to retain clinical meaning
(i.e. laboratory values for “high-abnormal” range were maintained in
that value range).
Genotype
Genomic data was simulated by adding the known causal variant to
variant tables generated from publicly available trios from the 1000
Genomes Project to prevent identification of a real person. However,
the known causal variant was not given key annotations such as
functional and conservation scores that are used in the DDSS’s
explanation of variant and zygosity severity scores.
Processing
Resulting simulated patient data for 3 simulated patients was loaded
into the Logica platform for user testing and run through the cTAKES
Clinical Pipeline using default settings.
*3 simulated patients of escalating complexity with notes and clinical findings were created based on 3
real Geisinger patients with known genetic disorders. Two others were used in earlier testing and the
demo video (https://simulconsult.com/videogpacss).
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Supplemental figure A
SUPPLEMENTARY Figure A: SimulConsult interface showing Gene zygosities found in the
genomic analysis
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Supplemental Material - GPACSS User Testing Interview Guide

Consent/Recording:
Thank you for agreeing to participate in our testing of the Genome-Phenome Archiving and
Communication System (GPACS). Our goal today is to have you simulate a clinical process for each of 3
case scenarios - going from assessment to diagnosis after genetic sequencing results. We will be
recording how you use GPACS in each case, how easy/difficult it is to find what you are looking for, what
works/not for you, and what your thoughts are on how helpful it is in this process. I will also be asking
you to “think aloud” as you are going through this – we will be recording your thoughts and clicks, and I
will be asking general and specific questions throughout.
You can stop participating at any time. At the end you will receive a gift card.

Start recording

Introduction and video instruction:
I’m going to present you with 3 clinical vignettes about cases where you might order genome/exome
sequencing for the patient. After the first vignette I will show a short video that will orient you to the
Genome-Phenome analyzer and how to use it to help you facilitate the diagnostic process.
I’ll be asking questions as you go through each vignette, and we can watch the video again if needed.
This video will orient you to the GPACS tool as it would look in the EHR once you open with findings and
start the process of reviewing the case and the genetic results. The tool finds many, but not all findings in
the EHR. We will start the first vignette after you watch the video:
launch user testing orientation video
For each vignette: Imagine you have returned the patient’s chart and have opened Simulconsult with
prior findings. Look around and see if you can see the findings and import the genome. Then let’s do like
the video and see the findings, review the chart, and create the report
Tester process for each vignette:
1.
2.
3.
4.
5.

Open with pre-loaded findings and any family history
Import genomic results
Review flagged findings and “Mentions”
Record pertinent negatives
Make diagnosis and create report

Launch GPACS Logica sandbox
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Vignette 1:
You have seen a 27 year old male with pectus excavatum and tall stature. As part of your clinical process
you have ordered genomic sequencing for this patient. After the genetic information is available, you
return to the patient’s chart to review the genetic information in light of the patient’s other medical
information. You launch the GPACSS system and click in as a permitted user, choose a patient, and
launch SimulConsult with the prior findings already entered

Vignette 2:
You have seen a 21 year old female with seizures who sometimes has some hand wringing. As part of
your clinical process you have ordered genomic sequencing for this patient. After the genetic information
is available, you return to the patient’s chart to review the genetic information in light of the patient’s
other medical information. You open an encounter and launch the GPACSS system with Your prior
findings

Vignette 3:
You have seen a 14 year old female with seizures and a small head. As part of your clinical process you
have ordered genomic sequencing for this patient. After the genetic information is available, you return
to the patient’s chart to review the genetic information in light of the patient’s other medical
information. You open an encounter and launch the GPACSS system with Your prior findings

Interview Questions during each case scenario (asked as appropriate in vignettes):
General question throughout: Why did you look there? Do that? Think of that? Click that? You seem
to be clicking around – are you looking for something specific?

•

How does the GPACSS process fit with what would normally do in this process?
• How does GPACSS help/not?
• What do the numbers/severity score mean to you?
• What does the list/shading/differentials/graphics mean to you (or do for you)? (at each
screen)
• How do they help (or not)?

•

How does GPACSS help you locate info in chart and decide whether it is relevant? How does the
ordering of findings by usefulness help you focus on relevant information?

•

What questions does using GPACSS bring up for you as you’re using it?
• Thoughts on the experience so far?

•

What are your thoughts about the report? How would you use it? What are your questions about it?
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•

What would you do next in this process/case?

•

Is there anything in this process you WOULDN’T use for this case? (why?)

•

How did using GPACSS for this case compare with your typical process?
•
•

•
•
•

BMJ Health Care Inform

Was GPACSS intuitive?
What did you think about the filtering/flagging?
• How did it make the process easier/harder?
• What questions did you have about it as you were using it for this case?
• Would you like more text before or after the text in bold of the mentions of a
finding in the chart?
• Would you like a hyperlink to open up the whole note in which a mention was
found?
How difficult / easy? What needs to change?
Does this process fit with workflow? How/not?

What would you do next with this case after reviewing the exome results?

CLOSING QUESTIONS:
1. How satisfied are you with whole GPACS process? (0-10 scale from “not at all” to “extremely
satisfied”)
 Explain
2. How often do you think you would you use it when receiving exome results? (0-10 scale from never
to always)
 Explain
3. How confident were you with the GPACSS diagnostic support process? (0-10 scale from “not at all”
to “extremely confident”)
 Explain
4. How comfortable were you with the flagged findings and chart context filters? (0-10 scale from “not
at all” to “extremely comfortable”)
5. How do you see yourself using this for your patients regularly?
 What works for you to use this regularly
 What needs changing for you to use it regularly?
6.
7.
8.
9.
10.

How does GPACSS improve/not the process for you?
Workflow thoughts? Where to implement? What needed to implement?
What sort of training would you need to use this regularly?
Is this something you would integrate into practice? Explain.
How would you use it?
• How would colleagues use it?
• Other feedback?

Kulchak Rahm A, et al. BMJ Health Care Inform 2021; 28:e100331. doi: 10.1136/bmjhci-2021-100331

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Health Care Inform

DEMOGRAPHIC QUESTIONS:
1. How long have you been at Geisinger?
2. How long have you been at your current position?
3. Current department and clinical role?
4. How often do you order exomes and report results?
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